NCT05357651View on ClinicalTrials.gov

A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）

PHASE1RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

August 12, 2022

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2028

Conditions

Solid TumorLymphoma

Interventions

DRUG

LB1410

anti-PD-1 and anti-TIM-3 bispecific antibody

Trial Locations (1)

Unknown

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors

lead

L & L Bio Co., Ltd., Ningbo, China

INDUSTRY